(Q53854337)

21 May 2018

title

Update on Hepatitis B and C Coinfection in HIV. (English)

1 reference

21 May 2018

0 references

Patrick Yachimski

1

1 reference

21 May 2018

Raymond T Chung

series ordinal

2

1 reference

21 May 2018

publication date

1 July 2005

1 reference

21 May 2018

number of pages

10

1 reference

Current infectious disease reports

inferred from page(s)

published in

1 reference

21 May 2018

volume

7

1 reference

21 May 2018

issue

4

1 reference

21 May 2018

page(s)

299-308

1 reference

21 May 2018

The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men.

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11908-005-0063-4

Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11908-005-0063-4

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11908-005-0063-4

Survival of Human Immunodeficiency Virus–Infected Liver Transplant Recipients

21 January 2018

1 reference

12 December 2020

Human Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent Viruses

1 reference

12 December 2020

Analysis of successful immune responses in persons infected with hepatitis C virus

1 reference

12 December 2020

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects

1 reference

12 December 2020

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

12 December 2020

High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.

1 reference

12 December 2020

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

1 reference

12 December 2020

The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.

1 reference

12 December 2020

Analysis of a successful immune response against hepatitis C virus

1 reference

12 December 2020

Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future

1 reference

12 December 2020

Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Prevalence of human immunodeficiency virus testing in patients with hepatitis B and C infection

1 reference

12 December 2020

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

12 December 2020

Hepatitis C and progression of HIV disease

1 reference

12 December 2020

Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic

1 reference

12 December 2020

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

12 December 2020

Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin

1 reference

12 December 2020

HIV/Hepatitis B and C co-infection: pathogenic interactions, natural history and therapy.

1 reference

12 December 2020

Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease

1 reference

12 December 2020

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

12 December 2020

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

12 December 2020

Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy

1 reference

12 December 2020

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

12 December 2020

Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons

1 reference

12 December 2020

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

12 December 2020

HIV-1 and hepatitis B virus: time for a re-think?

1 reference

12 December 2020

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

12 December 2020

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

1 reference

12 December 2020

Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients

1 reference

12 December 2020

Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection

1 reference

12 December 2020

Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study

1 reference

12 December 2020

Management of hepatitis B: 2000--summary of a workshop

1 reference

12 December 2020

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

1 reference

12 December 2020

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

1 reference

12 December 2020

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

1 reference

12 December 2020

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

12 December 2020

Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection

1 reference

12 December 2020

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

1 reference

12 December 2020

Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy

1 reference

12 December 2020

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

12 December 2020

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection

1 reference

12 December 2020

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

12 December 2020

Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV.

1 reference

12 December 2020

Low Prevalence of Ongoing Hepatitis B Viremia in HIV-Positive Individuals with Isolated Antibody to Hepatitis B Core Antigen

1 reference

12 December 2020

Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin

1 reference

12 December 2020

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

12 December 2020

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

12 December 2020

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

1 reference

12 December 2020

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

1 reference

12 December 2020

Hepatitis C viremia persistently suppressed by HAART.

1 reference

12 December 2020

Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy

1 reference

12 December 2020

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

1 reference

12 December 2020

Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival

1 reference

12 December 2020

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.

1 reference

12 December 2020

The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients

1 reference

12 December 2020

Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection

1 reference

12 December 2020

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

1 reference

12 December 2020

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

12 December 2020

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus

1 reference

12 December 2020

Anemia during treatment of hepatitis C in HIV-infected patients

1 reference

12 December 2020

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

1 reference

12 December 2020

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa

1 reference

12 December 2020

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

12 December 2020

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report

1 reference

12 December 2020

Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection

1 reference

12 December 2020

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

1 reference

12 December 2020

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

1 reference

12 December 2020

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

1 reference

12 December 2020

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

12 December 2020

Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects

1 reference

12 December 2020

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.

1 reference

12 December 2020

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

12 December 2020

Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient

1 reference

12 December 2020

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

1 reference

12 December 2020

Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients

1 reference

12 December 2020

Major hemorrhage after percutaneous liver biopsy in patients with AIDS

1 reference

12 December 2020

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

12 December 2020

10.1007/S11908-005-0063-4

Identifiers

DOI

1 reference

21 May 2018

1 reference

21 May 2018